Ex­clu­sive: Col­umn Group rais­es a new $400M+ fund and R&D hub for sin­gle-as­set bi­o­log­ics com­pa­nies

As the biotech in­dus­try grap­ples with how to fund drug de­vel­op­ment in a world of in­creas­ing re­search costs, ris­ing drug prices and gov­ern­ment-re­lat­ed risk, a lega­cy in­vestor is tak­ing a dif­fer­ent ap­proach for its 10th fund.

The Col­umn Group told End­points News ex­clu­sive­ly on Thurs­day that it has raised over $400 mil­lion for a new fund to back sin­gle-as­set bi­o­log­ic com­pa­nies de­rived from its ex­ten­sive Rolodex of re­searchers and en­tre­pre­neurs. The fund will bring the group’s as­sets un­der man­age­ment to around $4 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER